Citations

Showing 10 of 108083 citations.

Hermansky-Pudlak syndrome subtype 5 (HPS-5) novel mutation in a 65 year-old with oculocutaneous hypopigmentation and mild bleeding diathesis: The importance of recognizing a subtle phenotype
Chen, Dong , Majerus, Julie A. , Coon, Lea M., He, Rong , Pruthi, Rajiv K. , Nichols, William L., Botero, Juliana Perez , Warad, Deepti M, Chen, Dong , Warad, Deepti

Mayo Clinic

Platelets | November 1, 2017 | Volume: 29 | Issue: 1 | Pages: 91-94

10.1080/09537104.2017.1361019 | PMID 29090612 Get It

Handgrip Strength in Chronic Obstructive Pulmonary Disease: Ready for Prime Time or Frailty Research Tool?
Kennedy, Cassie C. , Kennedy, Cassie C

Mayo Clinic

Annals of the American Thoracic Society | November 1, 2017 | Volume: 14 | Issue: 11 | Pages: 1630-1631

10.1513/annalsats.201706-487ed | PMID 29090996 Get It

Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis
Mayumi, Toshihiko , Okamoto, Kohji , Takada, Tadahiro , Strasberg, Steven M. , Solomkin, Joseph S. , Schlossberg, David, Pitt, Henry A. , Yoshida, Masahiro , Gomi, Harumi , Miura, Fumihiko, Garden, O. James , Kiriyama, Seiki , Yokoe, Masamichi, Endo, Itaru , Asbun, Horacio J. , Iwashita, Yukio , Hibi, Taizo , Umezawa, Akiko , Itoi, Takao , Hata, Jiro , Hwang, Tsann‐Long , Dervenis, Christos, Asai, Koji , Mori, Yasuhisa , Huang, Wayne Shih‐Wei, Belli, Giulio, Jagannath, P., Cherqui, Daniel , Kozaka, Kazuto , Baron, Todd H. , Santibáñes, Eduardo de , Higuchi, Ryota , Wada, Keita, Gouma, Dirk J., Deziel, Daniel J., Liau, Kui‐Hin, Wakabayashi, Go , Padbury, Robert , Jonas, Eduard , Supe, Avinash , Singh, Harjit , Gabata, Toshifumi , Chan, Angus C. W., Lau, Wan Yee , Fan, Sheung Tat , Chen, Miin‐Fu , Ker, Chen‐Guo , Choi, In‐Seok , Kim, Myung‐Hwan , Kitano, Seigo, Inomata, Masafumi , Inui, Kazuo, Sumiyama, Yoshinobu, Yamamoto, Masakazu , Suzuki, Kenji S. , Han, Ho-Seong , Mukai, Shuntaro , Yoon, Yoo-Seok , Yoon, Dong Sup , Hirata, Koichi , Jonas, Eduard

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | November 1, 2017 | Volume: 25 | Issue: 1 | Pages: 96-100

10.1002/jhbp.519 | PMID 29090868 Get It

Abstract Management bundles that define items or procedures strongly recommended in clinical practice have been used in many guidelines in recent years. Application of these bundles facilitates the adaptation of guidelines and helps improve the prognosis of target diseases. In Tokyo Guidelines 2013 ( TG 13), we proposed management bundles for acute cholangitis and cholecystitis. Here, in Tokyo Guidelines 2018 ( TG 18), we redefine the management bundles for acute cholangitis and cholecystitis. Critical parts of the bundles in TG 18 include the diagnostic process, severity assessment, transfer of patients if necessary, and therapeutic approach at each time point. Observance of these items and procedures should improve the prognosis of acute cholangitis and cholecystitis. Studies are now needed to evaluate the dissemination of these TG 18 bundles and their effectiveness. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47 . Related clinical questions and references are also included.
Key findings from the Atahualpa Project: what should we learn?
Brutto, Óscar H. Del , Mera, Robertino M. , Castillo, Pablo R. , Brutto, Víctor J. Del , Castillo, Pablo R , Del Brutto, Victor J

Mayo Clinic

Expert Review of Neurotherapeutics | November 1, 2017 | Volume: 18 | Issue: 1 | Pages: 5-8

10.1080/14737175.2018.1400382 | PMID 29088979 Get It

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
Meehan, Terrence F. , Goldstein, Theodore C. , Murakami, Mark A. , Brabetz, Sebastian , Gu, Zhiping , Wiser, Jeffrey A., Dunn, Patrick , Begley, Dale A. , Krupke, Debra M. , Bertotti, Andrea , Bruna, Alejandra , Brush, Matthew , Byrne, Annette T. , Caldas, Carlos , Christie, Amanda L., Clark, Dominic A. , Dowst, Heidi , Dry, Jonathan R. , Doroshow, James H. , Duchamp, Olivier, Ferretti, Stéphane , Frese, Kristopher K. , Goodwin, Neal , Greenawalt, Danielle M., Haendel, Melissa , Hermans, Els , Houghton, Peter J. , Jonkers, Jos , Kemper, Kristel , Khor, Tin Oo, Lloyd, K. C. Kent , Mason, Jeremy , Médico, Enzo , Olson, James M. , Peeper, Daniel S. , Seong, Je Kyung , Trusolino, Livio , Vinolo, Emilie, Wechsler‐Reya, Robert J. , Weinstock, David M. , Welm, Alana L. , Weroha, S. John , Pfister, Stefan M. , Kool, Marcel , Parkinson, Helen , Butte, Atul J. , Bult, Carol J. , Haendel, Melissa , Caldas, Carlos , Pfister, Stefan M , Conte, Nathalie , Inghirami, Giorgio , Evrard, Yvonne A. , Lewis, Michael T. , Neuhauser, Steven B. , Rueda, Oscar M. , Amant, Frédéric

Mayo Clinic

Cancer Research | November 1, 2017 | Volume: 77 | Issue: 21 | Pages: e62-e66

10.1158/0008-5472.can-17-0582 | PMID 29092942 Get It

Abstract Patient-derived tumor xenograft (PDX) mouse models have emerged as an important oncology research platform to study tumor evolution, mechanisms of drug response and resistance, and tailoring chemotherapeutic approaches for individual patients. The lack of robust standards for reporting on PDX models has hampered the ability of researchers to find relevant PDX models and associated data. Here we present the PDX models minimal information standard (PDX-MI) for reporting on the generation, quality assurance, and use of PDX models. PDX-MI defines the minimal information for describing the clinical attributes of a patient's tumor, the processes of implantation and passaging of tumors in a host mouse strain, quality assurance methods, and the use of PDX models in cancer research. Adherence to PDX-MI standards will facilitate accurate search results for oncology models and their associated data across distributed repository databases and promote reproducibility in research studies using these models. Cancer Res; 77(21); e62–66. ©2017 AACR.
Impact of Diabetes Mellitus on the Evaluation of Stable Chest Pain Patients: Insights From the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) Trial
Sharma, Abhinav , Sekaran, Nishant K., Coles, Adrian , Pagidipati, Neha J. , Hoffmann, Udo , Lee, Kerry L. , Al‐Khalidi, Hussein R. , Lu, Michael T. , Pellikka, Patricia A. , Truong, Quynh A. , Douglas, Pamela S. , Pellikka, Patricia A , Douglas, Pamela S , Mark, Daniel B.

Mayo Clinic

Journal of the American Heart Association | November 1, 2017 | Volume: 6 | Issue: 11 | Pages: No page available

10.1161/jaha.117.007019 | PMID 29089344 Get It

Background The impact of diabetes mellitus on the clinical presentation and noninvasive test ( NIT ) results among stable outpatients presenting with symptoms suggestive of coronary artery disease ( CAD ) has not been well described. Methods and Results The PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial enrolled 10 003 patients with known diabetic status, of whom 8966 were tested as randomized and had interpretable NIT results (1908 with diabetes mellitus, 21%). Differences in symptoms and NIT results were evaluated using logistic regression. Patients with diabetes mellitus (versus without) were similar in age (median 61 versus 60 years) and sex (female 54% versus 52%), had a greater burden of cardiovascular comorbidities, and had a similar likelihood of nonchest pain symptoms (29% versus 27%). The Diamond‐Forrester/Coronary Artery Surgery Study score predicted that patients with diabetes mellitus (versus without) had similar likelihood of obstructive CAD (low 1.8% versus 2.7%; intermediate 92.3% versus 92.6%; high 5.9% versus 4.7%). Physicians estimated patients with diabetes mellitus to have a higher likelihood of obstructive CAD (low to very low: 28.3% versus 40.1%; intermediate 63.9% versus 55.9%; high to very high 7.8% versus 4.0%). Patients with diabetes mellitus (versus without) were more likely to have a positive NIT result (15% versus 11%; adjusted odds ratio, 1.23; P =0.01). Conclusions Stable chest pain patients with and without diabetes mellitus have similar presentation and pretest likelihood of obstructive CAD ; however, physicians perceive that patients with diabetes mellitus have a higher pretest likelihood of obstructive CAD , an assessment supported by increased risk of a positive NIT . Further evaluation of diabetes mellitus's influence on CAD assessment is required. Clinical Trial Registration URL : https://www.clinicaltrials.gov . Unique identifier: NCT 01174550.
The limbic and neocortical contribution of α‐synuclein, tau, and amyloid β to disease duration in dementia with Lewy bodies
Ferman, Tanis J. , Aoki, Naoya , Murray, Melissa E. , Graff‐Radford, Neill R. , Gerpen, Jay A. van, Uitti, Ryan J. , Graff‐Radford, Jonathan, Pedraza, Otto , Kantarci, Kejal , Crook, Julia E. , Van Gerpen, Jay A, Kantarci, Kejal , Murray, Melissa E , Ferman, Tanis J , Wszołek, Zbigniew K. , Graff‐Radford, Jonathan , Boeve, Bradley F. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | October 31, 2017 | Volume: 14 | Issue: 3 | Pages: 330-339

10.1016/j.jalz.2017.09.014 | PMID 29100980 Get It

AbstractIntroductionWe sought to assess the individual and combined contribution of limbic and neocortical α‐synuclein, tau, and amyloid β (Aβ) to duration of illness in dementia with Lewy bodies (DLB).MethodsQuantitative digital pathology of limbic and neocortical α‐synuclein, tau, and Aβ was assessed in 49 patients with clinically probable DLB. Regression modeling examined the unique and shared contribution of each pathology to the variance of illness duration.ResultsPatients with diffuse Lewy body disease had more severe pathology of each type and a shorter duration of illness than individuals with transitional Lewy body disease. The three pathologies accounted for 25% of the total variance of duration of illness, with 19% accounted for by α‐synuclein alone or in combination with tau and Aβ. When the diffuse Lewy body disease group was examined separately, α‐synuclein deposition significantly exceeded that of tau and Aβ. In this model, 20% of 24% total variance in the model for duration of illness was accounted for independently by α‐synuclein.DiscussionIn DLB, α‐synuclein is an important predictor of disease duration, both independently and synergistically with tau and Aβ.
Atrial Fibrillation Should Guide Prophylactic Tricuspid Procedures During Left Ventricular Assist Device Implantation
Anwer, Lucman A. , Tchantchaleishvili, Vakhtang , Poddi, Salvatore , Daly, Richard C. , Joyce, Lyle D., Kushwaha, Sudhir S. , Topilsky, Yan , Stulak, John M., Maltais, Simon, Topilsky, Yan , Tchantchaleishvili, Vakhtang , Topilsky, Yan

Mayo Clinic

ASAIO Journal | October 31, 2017 | Volume: 64 | Issue: 5 | Pages: 586-593

10.1097/mat.0000000000000698 | PMID 29088022 Get It

Atrial fibrillation (AF) and tricuspid regurgitation (TR) are common in patients undergoing left ventricular assist device (LVAD) implantation. TR progression is associated with the presence of AF, and questions remain as to who benefits from tricuspid valve procedures (TVPs). We examined the impact of preoperative AF on TR progression after LVAD implantation. From February 2007 to May 2014, 250 patients underwent LVAD implantation at our institution. Patients with concomitant TVP were excluded from this analysis (113 patients). The indication for LVAD was destination therapy in 80 patients (58%) and the etiology of heart failure was ischemic in 73 (53%). Follow-up was available in all early survivors for a total of 393 patient-years of support. Of the 137 non-TVP patients, 52 (38%) had AF preoperatively. Observed overall survival at 1, 3, and 5 years was 82%, 67%, and 55%, respectively. Median grade of TR increased from 2 preoperatively to 3 (p = 0.04) in the AF group and 2.2 (p = 0.75) in the non-AF group at 5 years of follow-up. We also observed a significant difference in the degree of TR between groups at 3 months (p = 0.03) and 12 months (p = 0.01) postimplantation, and a trend toward significance at 18 (p = 0.06) and 24 (p = 0.07) months. The presence of AF is associated with early progression of TR after LVAD implantation. Addition of concomitant TVP in patients with preoperative AF may be considered in patients with less than severe TR. The impact of these findings on right ventricular failure/remodeling remains to be evaluated.
Subcostal Trocar Approach Using Four 5-mm with Exclusive Removal (STAUFFER): An Efficient and Useful Technique for Laparoscopic Cholecystectomy
Tsamalaidze, Levan , Permenter, S., Stauffer, John , Permenter, Samantha L, A Stauffer, John

Mayo Clinic

Journal of Laparoendoscopic & Advanced Surgical Techniques | October 31, 2017 | Volume: 28 | Issue: 3 | Pages: 311-319

10.1089/lap.2017.0554 | PMID 29087805 Get It

The Design and Development of Active Compression Garments for Orthostatic Intolerance
Duvall, Julia, Granberry, Rachael , Dunne, Lucy E. , Holschuh, Brad , Kelly, Kevin L. , Johnson, Bruce , Johnson, Christopher D. , Joyner, Michael J.

Mayo Clinic

2017 Design of Medical Devices Conference | October 31, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/dmd2017-3480 Get It

Current compression garments are often made from a spandex-type elastic material with static levels of compression and can become uncomfortable and difficult to don/doff [1]. This limits their usability, especially for unhealthy or aging populations. The only current alternative to elastic compression stockings are inflatable compression sleeves that are controllable, but highly immobile and must be tethered to an inflation source [2]. Neither design offers a solution that is simultaneously low profile, mobile, and controllable. Here we present the design and development of compression garments with embedded shape-changing materials that can produce controllable compression without the need for a bulky inflation system. This active materials approach enables dynamic control over the degree, timing and location of compression, and allows for graded, synchronized, pulsed, and peristaltic compression patterns, which provide the medical benefit of moving fluid in the body [2]. Such a design combines the best features of both elastic and inflatable compression garments: a slim, low-profile form factor that is easy to don/doff and provides dynamic control. Shape memory alloy (SMA) coil actuators, as described by Holschuh et al., [3] have the ability to apply compressive forces to the body when paired with passive textiles and wrapped circumferentially around the body. These actuators are engineered to contract when heated, creating controllable forces and displacements that are modulated through an applied current. SMA compression garments (SMA-CG) have important applications, from consumer uses to clinical interventions, including: augmenting venous return for conditions of orthostatic intolerance (e.g., postural orthostatic tachycardia syndrome (POTS)); cardiac rehabilitation in heart failure patients; lymphedema venous insufficiency; reducing deep vein thrombosis (DVT) risk; sports performance; and countermeasures for flight or space flight. While the potential uses for this technology are broad, the basic design is similar across many conditions. Key research areas include: 1) identifying and addressing design considerations relevant to prototype development of SMA-CG; 2) determining the compression thresholds needed to dynamically oppose orthostatic changes; and 3) evaluating the effectiveness of the prototypes for augmented venous return by synchronizing compression during cardiac diastole. Here, we focus on the first question: design of SMA-CG prototypes.